{"id":"NCT01712984","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years","officialTitle":"Immunogenicity and Safety Trial of Quadrivalent Influenza Vaccine Administered by Intradermal Route in Adult Subjects Aged 18 Through 64 Years","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10","primaryCompletion":"2013-06","completion":"2013-10","firstPosted":"2012-10-24","resultsPosted":"2014-02-10","lastUpdate":"2015-05-07"},"enrollment":3360,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation","otherNames":["QIV ID"]},{"type":"BIOLOGICAL","name":"Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal","otherNames":["Fluzone® Intradermal"]},{"type":"BIOLOGICAL","name":"Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal","otherNames":["Fluzone® Intradermal"]}],"arms":[{"label":"QIV ID Vaccine Group","type":"EXPERIMENTAL"},{"label":"TIV ID1 Vaccine Group","type":"ACTIVE_COMPARATOR"},{"label":"TIV ID2 Group","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of the study is to demonstrate safety and immunogenicity of the quadrivalent influenza intradermal (QIV-ID) vaccine compared to the trivalent influenza vaccine (TIV) containing the B strain from the primary (Yamagata) lineage (TIV-ID1) and the trivalent influenza vaccine containing B strain from the alternate (Victoria) lineage (TIV-ID2) vaccines in producing protection against four strains of influenza virus.\n\nPrimary Objective:\n\n* To demonstrate that QIV-ID induces an immune response (as assessed by hemagglutination inhibition (HAI) geometric mean titers (GMTs) and seroconversion rates) that is non-inferior to responses induced by TIV-ID1 and TIV-ID2 for the 4 virus strains at 28 days post-vaccination.\n\nSecondary Objectives:\n\n* To demonstrate that each B strain in QIV-ID induces an immune response (as assessed by HAI GMTs and seroconversion rates) that is superior to the response induced by the TIV-ID that does not contain the corresponding B strain.\n* To describe the rate of post-vaccination seroprotection induced by QIV-ID and TIV-ID.\n* To describe post-vaccination immunogenicity stratified by age (18-49 years and 50-64 years), race, ethnicity, gender, previous vaccination status, and baseline seropositivity status.\n* To describe the safety profile for subjects who receive QIV-ID and TIV-ID.\n\nObservational Objectives:\n\n* To demonstrate non-inferiority of QIV-ID compared to TIV-ID in terms of all Grade 2 or Grade 3 solicited systemic reactions combined\n* To demonstrate non-inferiority of QIV-ID compared to TIV-ID in terms of all Grade 3 solicited injection site reactions combined.","primaryOutcome":{"measure":"Geometric Mean Titers Against the Influenza Virus Antigens Following Vaccination With Either a Quadrivalent Influenza Vaccine or a Trivalent Influenza Vaccine Administered by Intradermal Route","timeFrame":"Day 28 post-vaccination","effectByArm":[{"arm":"QIV ID Vaccine Group","deltaMin":589,"sd":null},{"arm":"TIV ID1 Vaccine Group","deltaMin":728,"sd":null},{"arm":"TIV ID2 Vaccine Group","deltaMin":635,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":15},"locations":{"siteCount":38,"countries":["United States"]},"refs":{"pmids":["25613721","31537446"],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":1672},"commonTop":["Injection site Pain","Injection site Pruritus","Injection site Erythema","Headache","Myalgia"]}}